Dataset Information


Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.

ABSTRACT: Senescent cells within the tumor microenvironment (TME) adopt a proinflammatory, senescence-associated secretory phenotype (SASP) that promotes cancer initiation, progression, and therapeutic resistance. Here, exposure to palbociclib (PD-0332991), a CDK4/6 inhibitor, induces senescence and a robust SASP in normal fibroblasts. Senescence caused by prolonged CDK4/6 inhibition is DNA damage-independent and associated with Mdm2 downregulation, whereas the SASP elicited by these cells is largely reliant upon NF-?B activation. Based upon these observations, it was hypothesized that the exposure of nontransformed stromal cells to PD-0332991 would promote tumor growth. Ongoing clinical trials of CDK4/6 inhibitors in melanoma prompted a validation of this hypothesis using a suite of genetically defined melanoma cells (i.e., Ras mutant, Braf mutant, and Ras/Braf wild-type). When cultured in the presence of CDK4/6i-induced senescent fibroblasts, melanoma cell lines exhibited genotype-dependent proliferative responses. However, in vivo, PD-0332991-treated fibroblasts enhanced the growth of all melanoma lines tested and promoted the recruitment of Gr-1-positive immune cells. These data indicate that prolonged CDK4/6 inhibitor treatment causes normal fibroblasts to enter senescence and adopt a robust SASP. Such senescent cells suppress the antitumor immune response and promote melanoma growth in immunocompetent, in vivo models.Implications: The ability of prolonged CDK4/6 inhibitor treatment to induce cellular senescence and a robust SASP in primary cells may hinder therapeutic efficacy and promote long-term, gerontogenic consequences that should be considered in clinical trials aiming to treat melanoma and other cancer types. Mol Cancer Res; 15(3); 237-49. ©2016 AACR.


PROVIDER: S-EPMC5334447 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5833767 | BioStudies
1000-01-01 | S-EPMC5513862 | BioStudies
2019-01-01 | S-EPMC6735661 | BioStudies
1000-01-01 | S-EPMC6075036 | BioStudies
2010-01-01 | S-EPMC2855904 | BioStudies
2019-01-01 | S-EPMC6907691 | BioStudies
2018-01-01 | S-EPMC5799282 | BioStudies
2019-01-01 | S-EPMC6862446 | BioStudies
2018-01-01 | S-EPMC5806534 | BioStudies
1000-01-01 | S-EPMC5861994 | BioStudies